In the event the class of drugs specified herein has previously been reviewed, the government solicits quotes for new Blanket Purchase Agreements (BPAs)/Voluntary Agreement for Retail Refunds (VARRs) to replace any existing BPAs/VARRs . The government will not consider existing BPA/VARR prices in the Uniform Formulary (UF) evaluation. Any existing BPA/VARR for this class of drugs will be terminated upon the conclusion of the UF decision.
| Meeting Date |
Review Type |
Drug Classes/New Drugs Under Review/Information for Manufacturers |
Meeting Window for Manufacturers to give Clinical/Cost Presentations |
|
February 2013
|
Class Review |
Topical Pain Agents |
January 2013 |
| Class Review |
Pulmonary-2 Agents: COPD |
| Class Review |
Anticoagulants |
| Designated Newly Approved Drugs |
Intermezzo |
|
May 2013
|
Class Review |
Gout |
March-April 2013 |
| Class Review |
Pulmonary-2 Agent: COPD |
| Class Review |
Tobacco Cessation Agents |
| Class Review |
Pulmonary-2 Agents |
| Clinical Presentations |
Corticosteroids-Immune Modulators |
| Clinical Presentations |
Self-Monitoring Blood Glucose Systems |
| Clinical Presentations |
Lancets |
|
August 2013
|
Class Review |
Corticosteroids-Immune Modulators |
June-July 2013
|
| Class Review |
Self-Monitoring Blood Glucose Systems |
| Class Review |
Rednin-Angiotensin Anithypertensives |
| Clinical Presentations |
Pulmonary-1 Agents |
|
November 2013
|
Class Revew |
Pulmonary-1 Agents |
September-October 2013 |
| Class Review |
Antilipidemics-1 |
| Class Review |
Benign Prostatic Hyperplasia Agents |
| Designated Newly Approved Drugs |
Binosto, Kazano, Nesina, Oseni |
Subject to Change Disclaimer
The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.
If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.